BTIG Maintains Buy on Astrana Health, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst David Larsen has maintained a Buy rating on Astrana Health (NASDAQ:ASTH) and raised the price target from $60 to $70.
October 03, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst David Larsen has maintained a Buy rating on Astrana Health and increased the price target from $60 to $70, indicating positive sentiment and potential upside.
The increase in price target from $60 to $70 by BTIG suggests a positive outlook for Astrana Health, likely leading to increased investor interest and potential stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100